Less than one in 10 individuals that would benefit from GLP-1 drugs such as Wegovy can access them, states the WHO as it releases its inaugural recommendations on the drugs.
With in excess of 1,000,000,000 people worldwide currently classified as obese, it is advocating for increased and just availability to this class of drugs.
Per estimates, more than two billion will be obese by 2030 unless action is taken.
"The new guidelines acknowledges that excess weight is a lifelong illness that can be addressed with thorough and continuous support," stated the agency's head Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and logistical bottlenecks are major barriers to universal availability to the jabs that can aid individuals in losing significant body mass, says the agency.
Weight-Loss Drug Scarcity
Despite the present most optimistic case, the manufacturing of these medications could only cover approximately 100 million people – less than 10% of those who need them, according to the health organization.
The recommendation encourages countries and companies to increase availability, via approaches like voluntary licensing.
The intellectual property rights on the active ingredient – the main ingredient of a leading brand – is due to expire in a number of nations in 2026.
How Obesity Injections Function
GLP-1 drugs replicate a body's own hormone to slow digestion, reduce hunger and boost feelings of fullness so people eat less.
Individuals usually start to lose weight within a few weeks of beginning the weekly injections.
Evidence points to users may see weight return a year later of stopping the drug, when their typical hunger resume.
Being above a healthy weight raises your chance for developing medical conditions, such as diabetes, heart disease, brain attack, and some malignancies.
Excess weight affects individuals in all nations and was associated with 3.7 million deaths worldwide in 2024, as per the health agency.
